Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors

Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination... Investigational New Drugs https://doi.org/10.1007/s10637-018-0601-1 PHASE I STUDIES Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors 1 2 3 4 5 Sandrine Hiret & Nicolas Isambert & Carlos Gomez-Roca & Jaafar Bennouna & Mouna Sassi & 5 6 7 3 Hélène de Mont-Serrat & Jean Fan & David Schnell & Jean-Pierre Delord Received: 29 November 2017 /Accepted: 5 April 2018 Springer Science+Business Media, LLC, part of Springer Nature 2018 Summary Background Afatinib, an irreversible ErbB family blocker, has shown synergistic antitumor activity and manageable tolerability in combination with chemotherapy. This phase I study assessed oral afatinib plus intravenous gemcitabine or docetaxel in patients with relapsed/refractory solid tumors. Methods Patients received afatinib (30, 40, or 50 mg) plus gemcitabine (1000 or 1250 mg/m )or docetaxel (60 or 75 mg/m ). Dose escalation proceeded via a 3 + 3 design until the maximum tolerated dose (MTD) was reached. Adverse events (AEs), pharmacokinetics and antitumor activity were also assessed. Results Dose-limiting toxicities during Cycle 1 were reported in 6/39 patients receiving afatinib/gemcitabine (most commonly diarrhea, thrombocytopenia and vomiting) and 16/54 patients receiving afatinib/docetaxel (most commonly febrile http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Investigational New Drugs Springer Journals

Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors

Loading next page...
 
/lp/springer_journal/phase-i-dose-escalation-trial-of-afatinib-an-irreversible-erbb-family-FK0GdFXbM8
Publisher
Springer US
Copyright
Copyright © 2018 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Pharmacology/Toxicology
ISSN
0167-6997
eISSN
1573-0646
D.O.I.
10.1007/s10637-018-0601-1
Publisher site
See Article on Publisher Site

Abstract

Investigational New Drugs https://doi.org/10.1007/s10637-018-0601-1 PHASE I STUDIES Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors 1 2 3 4 5 Sandrine Hiret & Nicolas Isambert & Carlos Gomez-Roca & Jaafar Bennouna & Mouna Sassi & 5 6 7 3 Hélène de Mont-Serrat & Jean Fan & David Schnell & Jean-Pierre Delord Received: 29 November 2017 /Accepted: 5 April 2018 Springer Science+Business Media, LLC, part of Springer Nature 2018 Summary Background Afatinib, an irreversible ErbB family blocker, has shown synergistic antitumor activity and manageable tolerability in combination with chemotherapy. This phase I study assessed oral afatinib plus intravenous gemcitabine or docetaxel in patients with relapsed/refractory solid tumors. Methods Patients received afatinib (30, 40, or 50 mg) plus gemcitabine (1000 or 1250 mg/m )or docetaxel (60 or 75 mg/m ). Dose escalation proceeded via a 3 + 3 design until the maximum tolerated dose (MTD) was reached. Adverse events (AEs), pharmacokinetics and antitumor activity were also assessed. Results Dose-limiting toxicities during Cycle 1 were reported in 6/39 patients receiving afatinib/gemcitabine (most commonly diarrhea, thrombocytopenia and vomiting) and 16/54 patients receiving afatinib/docetaxel (most commonly febrile

Journal

Investigational New DrugsSpringer Journals

Published: May 29, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off